Previous 10 | Next 10 |
Real-world effectiveness data on Oxbryta ® (voxelotor) in the treatment of sickle cell disease featured as oral presentation SOUTH SAN FRANCISCO, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), today announced its parti...
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced today it has received the 2020 Rare Impact Award ® for Industry Innovation from the National Organization for Rare Disorders (NORD)....
Four not-widely-followed biotech stocks were pitched at the recent Ira Sohn conference. Below is the full audio of the pitches, and a list of the publicly-traded landscape for each. For further details see: These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference
Keynote Address by U.S. Assistant Secretary for Health Admiral Brett P. Giroir, M.D. Discussion to Focus on SCD Treatment Progress and Management During COVID-19 Pandemic SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc...
Global Blood Therapeutics (NASDAQ: GBT ) +1.5% AH, has entered into an exclusive agreement with Biopharma-Middle East and Africa (Biopharma-MEA) for the distribution of Oxbryta (voxelotor) tablets in Bahrain, Kuwait, Oman, Qatar, S...
More than 100,000 people age 12 years and older with sickle cell disease (SCD) in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announce...
Introduction Global Blood Therapeutics ( GBT ) has been on my radar since late 2017 . My first article primarily detailed some risks involved with the company. Subsequent articles (from January 2018 on) became increasingly optimistic as I realized the potential in its, then, investigation...
The following slide deck was published by Global Blood Therapeutics, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Global Blood Therapeutics, Inc. (GBT) Q2 2020 Earnings Conference Call August 05, 2020, 16:30 ET Company Participants Stephanie Yao - Director, IR & Corporate Communications Ted Love - President, CEO & Director Jeffrey Farrow - CFO & Principal Accounting Officer Dav...
Global Blood Therapeutics (NASDAQ: GBT ) : Q2 GAAP EPS of -$0.86 beats by $0.29 . More news on: Global Blood Therapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...